Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.06
QDEL's Cash to Debt is ranked lower than
62% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. QDEL: 1.06 )
Ranked among companies with meaningful Cash to Debt only.
QDEL' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 1.85 Max: 13.76
Current: 1.06
0.09
13.76
Equity to Asset 0.52
QDEL's Equity to Asset is ranked lower than
58% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. QDEL: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
QDEL' s Equity to Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.77 Max: 0.85
Current: 0.52
0.52
0.85
F-Score: 7
Z-Score: 2.84
M-Score: -3.42
WACC vs ROIC
5.11%
-2.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -5.10
QDEL's Operating margin (%) is ranked higher than
52% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. QDEL: -5.10 )
Ranked among companies with meaningful Operating margin (%) only.
QDEL' s Operating margin (%) Range Over the Past 10 Years
Min: -13.49  Med: 7.17 Max: 31.99
Current: -5.1
-13.49
31.99
Net-margin (%) -7.33
QDEL's Net-margin (%) is ranked lower than
51% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.57 vs. QDEL: -7.33 )
Ranked among companies with meaningful Net-margin (%) only.
QDEL' s Net-margin (%) Range Over the Past 10 Years
Min: -9.94  Med: 4.51 Max: 20.49
Current: -7.33
-9.94
20.49
ROE (%) -6.04
QDEL's ROE (%) is ranked higher than
52% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.04 vs. QDEL: -6.04 )
Ranked among companies with meaningful ROE (%) only.
QDEL' s ROE (%) Range Over the Past 10 Years
Min: -9.43  Med: 4.31 Max: 26.77
Current: -6.04
-9.43
26.77
ROA (%) -3.24
QDEL's ROA (%) is ranked higher than
56% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.95 vs. QDEL: -3.24 )
Ranked among companies with meaningful ROA (%) only.
QDEL' s ROA (%) Range Over the Past 10 Years
Min: -5.92  Med: 2.99 Max: 21.27
Current: -3.24
-5.92
21.27
ROC (Joel Greenblatt) (%) -12.19
QDEL's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. QDEL: -12.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QDEL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -33.25  Med: 20.70 Max: 145.36
Current: -12.19
-33.25
145.36
Revenue Growth (3Y)(%) 7.60
QDEL's Revenue Growth (3Y)(%) is ranked higher than
66% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. QDEL: 7.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
QDEL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.1  Med: 6.60 Max: 20.5
Current: 7.6
-5.1
20.5
EBITDA Growth (3Y)(%) -7.00
QDEL's EBITDA Growth (3Y)(%) is ranked lower than
67% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. QDEL: -7.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QDEL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.8  Med: 6.80 Max: 245.9
Current: -7
-55.8
245.9
» QDEL's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

QDEL Guru Trades in Q1 2015

Joel Greenblatt 14,247 sh (New)
Mario Gabelli 600,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2015

QDEL Guru Trades in Q2 2015

Jim Simons 68,587 sh (New)
Joel Greenblatt 50,917 sh (+257.39%)
Mario Gabelli 600,000 sh (unchged)
» More
Q3 2015

QDEL Guru Trades in Q3 2015

Jim Simons 92,700 sh (+35.16%)
Mario Gabelli 600,000 sh (unchged)
Joel Greenblatt 17,774 sh (-65.09%)
» More
Q4 2015

QDEL Guru Trades in Q4 2015

Jim Simons 207,687 sh (+124.04%)
Mario Gabelli 600,000 sh (unchged)
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with QDEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 36.10
QDEL's Forward P/E is ranked lower than
86% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.80 vs. QDEL: 36.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 32.28
QDEL's Price/Owner Earnings (ttm) is ranked lower than
52% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.38 vs. QDEL: 32.28 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
QDEL' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.64  Med: 24.38 Max: 269.81
Current: 32.28
5.64
269.81
P/B 2.81
QDEL's P/B is ranked higher than
53% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. QDEL: 2.81 )
Ranked among companies with meaningful P/B only.
QDEL' s P/B Range Over the Past 10 Years
Min: 2.12  Med: 3.58 Max: 6.73
Current: 2.81
2.12
6.73
P/S 3.06
QDEL's P/S is ranked lower than
52% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.23 vs. QDEL: 3.06 )
Ranked among companies with meaningful P/S only.
QDEL' s P/S Range Over the Past 10 Years
Min: 1.81  Med: 3.94 Max: 6.17
Current: 3.06
1.81
6.17
PFCF 32.77
QDEL's PFCF is ranked lower than
58% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.91 vs. QDEL: 32.77 )
Ranked among companies with meaningful PFCF only.
QDEL' s PFCF Range Over the Past 10 Years
Min: 5.97  Med: 24.68 Max: 397.97
Current: 32.77
5.97
397.97
POCF 16.88
QDEL's POCF is ranked higher than
53% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.86 vs. QDEL: 16.88 )
Ranked among companies with meaningful POCF only.
QDEL' s POCF Range Over the Past 10 Years
Min: 5.39  Med: 19.58 Max: 401.39
Current: 16.88
5.39
401.39
EV-to-EBIT 187.79
QDEL's EV-to-EBIT is ranked lower than
97% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.90 vs. QDEL: 187.79 )
Ranked among companies with meaningful EV-to-EBIT only.
QDEL' s EV-to-EBIT Range Over the Past 10 Years
Min: -183.2  Med: 22.70 Max: 590.6
Current: 187.79
-183.2
590.6
EV-to-EBITDA 19.68
QDEL's EV-to-EBITDA is ranked lower than
72% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.72 vs. QDEL: 19.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
QDEL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -437.9  Med: 17.60 Max: 189.4
Current: 19.68
-437.9
189.4
Shiller P/E 59.47
QDEL's Shiller P/E is ranked lower than
87% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.04 vs. QDEL: 59.47 )
Ranked among companies with meaningful Shiller P/E only.
QDEL' s Shiller P/E Range Over the Past 10 Years
Min: 37.84  Med: 73.37 Max: 555.5
Current: 59.47
37.84
555.5
Current Ratio 7.81
QDEL's Current Ratio is ranked higher than
87% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.71 vs. QDEL: 7.81 )
Ranked among companies with meaningful Current Ratio only.
QDEL' s Current Ratio Range Over the Past 10 Years
Min: 1.77  Med: 3.96 Max: 7.81
Current: 7.81
1.77
7.81
Quick Ratio 6.95
QDEL's Quick Ratio is ranked higher than
88% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. QDEL: 6.95 )
Ranked among companies with meaningful Quick Ratio only.
QDEL' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 3.13 Max: 6.95
Current: 6.95
1.12
6.95
Days Inventory 127.91
QDEL's Days Inventory is ranked lower than
63% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 97.63 vs. QDEL: 127.91 )
Ranked among companies with meaningful Days Inventory only.
QDEL' s Days Inventory Range Over the Past 10 Years
Min: 73.81  Med: 90.85 Max: 130.22
Current: 127.91
73.81
130.22
Days Sales Outstanding 52.34
QDEL's Days Sales Outstanding is ranked higher than
81% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.21 vs. QDEL: 52.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
QDEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.59  Med: 62.37 Max: 76.33
Current: 52.34
21.59
76.33
Days Payable 45.35
QDEL's Days Payable is ranked lower than
60% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.98 vs. QDEL: 45.35 )
Ranked among companies with meaningful Days Payable only.
QDEL' s Days Payable Range Over the Past 10 Years
Min: 29.04  Med: 36.17 Max: 61.12
Current: 45.35
29.04
61.12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 157.27
QDEL's Price/Net Cash is ranked lower than
99% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.13 vs. QDEL: 157.27 )
Ranked among companies with meaningful Price/Net Cash only.
QDEL' s Price/Net Cash Range Over the Past 10 Years
Min: 7.53  Med: 31.43 Max: 192.73
Current: 157.27
7.53
192.73
Price/Net Current Asset Value 10.88
QDEL's Price/Net Current Asset Value is ranked lower than
68% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.92 vs. QDEL: 10.88 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
QDEL' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.45  Med: 10.41 Max: 45.85
Current: 10.88
3.45
45.85
Price/Tangible Book 2.81
QDEL's Price/Tangible Book is ranked lower than
59% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. QDEL: 2.81 )
Ranked among companies with meaningful Price/Tangible Book only.
QDEL' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.15  Med: 5.40 Max: 13.03
Current: 2.81
1.15
13.03
Price/Projected FCF 2.37
QDEL's Price/Projected FCF is ranked lower than
60% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. QDEL: 2.37 )
Ranked among companies with meaningful Price/Projected FCF only.
QDEL' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.06  Med: 2.93 Max: 7.08
Current: 2.37
1.06
7.08
Price/Median PS Value 0.78
QDEL's Price/Median PS Value is ranked higher than
65% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. QDEL: 0.78 )
Ranked among companies with meaningful Price/Median PS Value only.
QDEL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 0.86 Max: 1.52
Current: 0.78
0.26
1.52
Earnings Yield (Greenblatt) (%) 0.50
QDEL's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.10 vs. QDEL: 0.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QDEL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 3.60 Max: 17.3
Current: 0.5
0.2
17.3

More Statistics

Revenue(Mil) $184
EPS $ -0.40
Beta0.61
Short Percentage of Float23.16%
52-Week Range $13.21 - 24.59
Shares Outstanding(Mil)32.27

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 202 227
EPS($) 0.45 0.49
EPS without NRI($) 0.45 0.49

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:SZSE:300244, TSE:4544, NAS:CPHD, SZSE:300463, NAS:NEOG, NAS:KANG » details
Traded in other countries:QL1.Germany,
Quidel Corp was incorporated in the State of Delaware. It commenced operations in 1979. The Company operates in one business segment, which develops, manufactures and markets diagnostic testing solutions for applications mainly in infectious diseases and reproductive and women's health. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. The Company markets its products in the U.S. through a network of national and regional distributors, and a direct sales force. Its diagnostic testing solutions are designed to provide specialized results that serve a broad range of customers, by addressing varying requirements of ease of use, reduced cost, increased test accuracy and reduced time to result. Internationally, the Company sells and markets mainly in Japan, Europe, and the Middle East through exclusive distributor arrangements. During 2012, the Company continued to invest in several key areas: support for clinical research and expanding its communications through promotional campaigns, peer-reviewed technical publications, professional shows and exhibits, symposia, medical education and support of health economics and outcomes research. In 2012, it had manufacturing operations in San Diego and Santa Clara, California and Athens, Ohio Customers for IVD products are mainly centralized laboratories and physician offices and other decentralized non-institutional settings. Its objective is to build a broader-based diagnostic company, with products in market segments that are growing to realize increased shareholder value. The Company competes with several large pharmaceutical and diversified healthcare companies. The testing, manufacture and commercialization of its products are subjected to regulation by numerous governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies.
» More Articles for QDEL

Headlines

Articles On GuruFocus.com
Top Insider Buys Highlight: Quidel Corporation Jul 28 2014 
Weekly CEO Buys Highlight: TDY, KOPN, QDEL, SALM, FCAL Mar 24 2012 
CEO Buys 6/10/11: Quidel Corp. Jun 10 2011 
Quidel Corp. Reports Operating Results (10-Q) Oct 29 2010 
Quidel Corp. Reports Operating Results (10-Q) Jul 30 2010 
Quidel Corp. (QDEL) CFO John Matthew Radak buys 1,000 Shares Jun 22 2010 
Quidel Corp. Reports Operating Results (10-Q) May 03 2010 
MFI STOCK REVIEW: QUIDEL CORP (QDEL) Apr 01 2010 
Take Advantage of a 43% Upside on this Healthcare Reform Stock Trade Mar 30 2010 
Quidel Corp. Reports Operating Results (10-Q) Oct 21 2009 

More From Other Websites
QUIDEL CORP /DE/ Files SEC form 10-Q, Quarterly Report Apr 29 2016
Quidel to Present at the Bank of America Merrill Lynch 2016 Health Care Conference Apr 28 2016
Quidel to Present at the Bank of America Merrill Lynch 2016 Health Care Conference Apr 28 2016
Edited Transcript of QDEL earnings conference call or presentation 27-Apr-16 9:00pm GMT Apr 28 2016
Quidel reports 1Q loss Apr 27 2016
Quidel reports 1Q loss Apr 27 2016
Quidel Corp Earnings Call scheduled for 5:00 pm ET today Apr 27 2016
Quidel Reports First Quarter 2016 Financial Results Apr 27 2016
QUIDEL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 27 2016
Quidel Reports First Quarter 2016 Financial Results Apr 27 2016
Q1 2016 Quidel Corp Earnings Release - After Market Close Apr 27 2016
Q1 Earnings Lack Sheen: 5 MedTech Stocks to Bet On Apr 13 2016
Quidel to Hold First Quarter 2016 Financial Results Conference Call on April 27, 2016 Apr 12 2016
Quidel to Hold First Quarter 2016 Financial Results Conference Call on April 27, 2016 Apr 12 2016
QUIDEL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 30 2016
Quidel Corp. – Value Analysis (NASDAQ:QDEL) : March 15, 2016 Mar 15 2016
Quidel Corp. – Value Analysis (NASDAQ:QDEL) : March 15, 2016 Mar 15 2016
Quidel Corp. breached its 50 day moving average in a Bullish Manner : QDEL-US : March 14, 2016 Mar 14 2016
QUIDEL CORP /DE/ Financials Feb 26 2016
QUIDEL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Feb 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK